Dominik Lisowski

Dr. Dominik Lisowski


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DLDominik Lisowski
Dominik Lisowski
JTJannik Trömel
Jannik Trömel
PLPaul Lutyj
Paul Lutyj
VLVictor Lewitzki
Victor Lewitzki
PHPhilipp E. Hartrampf
Philipp E. Hartrampf
JTJörg Tamihardja
Jörg Tamihardja
This retrospective, single-institutional study investigated long-term outcome, toxicity and health-related quality of life (HRQoL) in meningioma patients after radiotherapy. We analyzed the data of 119 patients who received radiotherapy at our department from 1997 to 2014 for intracranial WHO grade I-III meningioma. Fractionated stereotactic radiotherapy (FSRT), intensity modulated radiotherapy (IMRT) or radiosurgery radiation was applied. The EORTC QLQ-C30 and QLQ-BN20 questionnaires were completed for assessment of HRQoL. Overall survival (OS) for the entire study group was 89.6% at 5 years and 75.9% at 10 years. Local control (LC) at 5 and 10 years was 82.4% and 73.4%, respectively. Local recurrence was observed in 22 patients (18.5%). Higher grade acute and chronic toxicities were observed in seven patients (5.9%) and five patients (4.2%), respectively. Global health status was rated with a mean of 59.9 points (SD 22.3) on QLQ-C30. In conclusion, radiotherapy resulted in very good long-term survival and tumor control rates with low rates of severe toxicities but with a deterioration of long-term HRQoL.

2 August 2022 in Cancers
Verified
Journal Article
Open access
PDF file
JTJörg Tamihardja
Jörg Tamihardja
LZLeonie Zehner
Leonie Zehner
PHPhilipp Hartrampf
Philipp Hartrampf
DLDominik Lisowski
Dominik Lisowski
SKSusanne Kneitz
Susanne Kneitz
Bülent PolatBülent Polat
Bülent Polat
Background: The study aimed to access the long-term outcome of salvage nodal radiotherapy (SNRT) in oligorecurrent prostate cancer. Methods: A total of 95 consecutive patients received SNRT for pelvic and/or extrapelvic nodal recurrence after prostate-specific membrane antigen (PSMA) or choline PET from 2010 to 2021. SNRT was applied as external beam radiotherapy with simultaneous integrated boost up to a median total dose of 62.9 Gy (EQD21.5Gy) to the recurrent lymph node metastases. The outcome was analyzed by cumulative incidence functions with death as the competing risk. Fine–Gray regression analyses were performed to estimate the relative hazards of the outcome parameters. Genitourinary (GU)/gastrointestinal (GI) toxicity evaluation utilized Common Toxicity Criteria for Adverse Events (v5.0). The results are as follows: the median follow-up was 47.1 months. The five-year biochemical progression rate (95% CI) was 50.1% (35.7–62.9%). Concomitant androgen deprivation therapy (ADT) was adminstered in 60.0% of the patients. The five-year biochemical progression rate was 75.0% (42.0–90.9%) without ADT versus 35.3% (19.6–51.4%) with ADT (p = 0.003). The cumulative five-year late grade 3 GU toxicity rate was 2.1%. No late grade 3 GI toxicity occured. Conclusions: Metastasis-directed therapy through SNRT for PET-staged oligorecurrent prostate cancer demonstrated a favorable long-term oncologic outcome. Omittance of ADT led to an increased biochemical progression.


2 October 2023 in Cancers
Verified
Journal Article
Open access
PDF file
DLDominik Lisowski
Dominik Lisowski
PLPaul Lutyj
Paul Lutyj
AAArya Abazari
Arya Abazari
SWStefan Dr. Weick
Stefan Dr. Weick
JTJan Traub
Jan Traub
JKJohannes Kraft
Johannes Kraft
Purpose: This study analyses a large number of cancer patients with CIEDs for device malfunction and premature battery depletion by device interrogation after each radiotherapy fraction and compares different guidelines in regard to patient safety. Methods: From 2007 to 2022, a cohort of 255 patients was analyzed for CIED malfunctions via immediate device interrogation after every RT fraction. Results: Out of 324 series of radiotherapy treatments, with a total number of 5742 CIED interrogations, nine device malfunctions (2.8%) occurred. Switching into back-up/safety mode and software errors occurred four times each. Once, automatic read-out could not be performed. The median prescribed cumulative dose at planning target volume (PTV) associated with CIED malfunction was 45.0 Gy (IQR 36.0–64.0 Gy), with a median dose per fraction of 2.31 Gy (IQR 2.0–3.0 Gy). The median maximum dose at the CIED at time of malfunction was 0.3 Gy (IQR 0.0–1.3 Gy). No correlation between CIED malfunction and maximum photon energy (p = 0.07), maximum dose at the CIED (p = 0.59) nor treatment localization (p = 0.41) could be detected. After excluding the nine malfunctions, premature battery depletion was only observed three times (1.2%). Depending on the national guidelines, 1–9 CIED malfunctions in this study would have been detected on the day of occurrence and in none of the cases would patient safety have been compromised. Conclusion: Radiation-induced malfunctions of CIEDs and premature battery depletion are rare. If recommendations of national safety guidelines are followed, only a portion of the malfunctions would be detected directly after occurrence. Nevertheless, patient safety would not be compromised.

4 November 2023 in BMC Neurology
Verified
Journal Article
Open access
PDF file
DLDominik Lisowski
Dominik Lisowski
PHPhilipp E. Hartrampf
Philipp E. Hartrampf
NHNatalie Hasenauer
Natalie Hasenauer
VNVera Nickl
Vera Nickl
CMCamelia-Maria Monoranu
Camelia-Maria Monoranu
JTJörg Tamihardja
Jörg Tamihardja
Background: Hematogenous tumor spread of malignant meningiomas occurs very rarely but is associated with very poor prognosis. Case presentation: We report an unusual case of a patient with a malignant meningioma who developed multiple metastases in bones, lungs and liver after initial complete resection of the primary tumor. After partial hepatic resection, specimens were histologically analyzed, and a complete loss of E-cadherin adhesion molecules was found. No oncogenic target mutations were found. The patient received a combination of conventional radiotherapy and peptide receptor radionuclide therapy (PRRT). Due to aggressive tumor behavior and rapid spread of metastases, the patient deceased after initiation of treatment. Conclusions: E-cadherin downregulation is associated with a higher probability of tumor invasion and distant metastasis formation in malignant meningioma. Up to now, the efficacy of systemic therapy, including PRRT, is very limited in malignant meningioma patients.

3 January 2022 in Research Square
Verified
Preprint
Open access
PDF file
DLDominik Lisowski
Dominik Lisowski
JTJannik Trömel
Jannik Trömel
PLPaul Lutyj
Paul Lutyj
VLVictor Lewitzki
Victor Lewitzki
PHPhilipp E. Hartrampf
Philipp E. Hartrampf
JTJörg Tamihardja
Jörg Tamihardja
Purpose: This retrospective, single-institutional study investigated long-term outcome, toxicity and health-related quality of life (HRQOL) in meningioma patients after radiotherapy. Methods: We analyzed the data of 119 patients who received radiotherapy at our department from 1997 to 2014 for intracranial WHO grade I-III meningioma. Fractionated stereotactic radiotherapy (FSRT), intensity modulated radiotherapy (IMRT) or radiosurgery radiation was applied using a linear accelerator. A median total dose of 54.7 Gy (IQR 54.0-60.0 Gy) was prescribed in median single doses of 1.8 Gy (IQR 1.8-1.9 Gy). Overall survival (OS) and local control (LC) rates were obtained. In addition, the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Core questionnaire (QLQ-C30) and the EORTC Brain Cancer Module (QLQ-BN20) were completed for assessment of HRQOL. Results were compared with normal population and with already published data. Results: OS for the entire cohort was 89.6% at 5 years and 75.9% at 10 years. LC at 5 and 10 years was 82.4% and 73.4%, respectively. Local recurrence was observed in 22 patients (18.5%). CTCAE grade ≥3 acute and chronic toxicities were observed in seven patients (5.9%) and five patients (4.2%), respectively. Global health status was rated with a mean of 59.9 points (SD 22.3) on QLQ-C30. HRQOL was lower after radiotherapy in comparison to normal population and to meningioma patients treated by surgery alone. Conclusion: Radiotherapy resulted in very good long-term survival and tumor control rates with low rates of severe toxicities. Nevertheless, long-term HRQOL may be negatively affected by radiotherapy.